Anti-tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia.
Chronic Lymphocytic Leukaemia (CLL) is an indolent disorder, which mainly affects older adults. Since the advent of chemoimmunotherapy, great progress has been made in its treatment. However, some patients develop a more aggressive form of the disease and are included in the group of high-risk CLL patients with a dismal prognosis and a need for new therapies. Maltotriose-modified poly(propylene imine) dendrimers were presented as potential agents in targeted therapy for CLL in the murine xenograft model. Tumour, brain and internal organs resected from NOD scid gamma mice were subjected to gross and histopathological evaluation. Results of ex vivo tissues examination indicated that open shell glycodendrimers prevented/inhibited the spread of CLL to the brain and internal organs and its transformation into a more aggressive form. The results of the study have a potentially important impact on the design of future personalized therapies as well as clinical trials.